KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities (2017 - 2025)

Amneal Pharmaceuticals has reported Other Non-Current Liabilities over the past 9 years, most recently at $19.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $19.1 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $19.1 million (changed N/A YoY), and the annual figure for FY2025 was $19.1 million, changed.
  • Other Non-Current Liabilities for Q4 2025 was $19.1 million at Amneal Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for AMRX hit a ceiling of $79.2 million in Q2 2022 and a floor of $1.0 million in Q3 2025.
  • Median Other Non-Current Liabilities over the past 5 years was $25.4 million (2024), compared with a mean of $30.8 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 97.56% in 2023 and later skyrocketed 1272.43% in 2024.
  • Amneal Pharmaceuticals' Other Non-Current Liabilities stood at $38.9 million in 2021, then tumbled by 84.76% to $5.9 million in 2022, then skyrocketed by 37.27% to $8.1 million in 2023, then soared by 221.73% to $26.2 million in 2024, then dropped by 26.94% to $19.1 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $19.1 million (Q4 2025), $1.0 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.